secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2025-05-27T23:59:59+00:00
Accession:  0000950170-25-077377
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo raises $80M in private placement; cash runway into 2028
-------------------------------------------------------------

- Gross proceeds ~$80M from sale of 20.79M shares and warrants at $2.8825/unit.
- Pre-funded warrants for 6.96M shares at $0.0001; common warrants expire May 28, 2029.
- Financing co-led by Frazier Life Sciences and Janus Henderson; J.P. Morgan, Oppenheimer placement agents.
- Proceeds to fund clinical programs including LX2006 efficacy readout expected by 2027.
- Private placement expected to close May 28, 2025; resale registration to be filed by June 27, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025077377/0000950170-25-077377-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000095017025077377/lxeo-20250527.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-077377

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer